Press Releases

Jun 20, 2022

New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

Read More

Jun 03, 2022

Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression

Read More

May 31, 2022

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

Read More

May 26, 2022

New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

Read More

May 26, 2022

Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

Read More

May 26, 2022

Veracyte to Present at Upcoming Investor Conferences

Read More

May 16, 2022

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

Read More

May 12, 2022

Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer

Read More

May 12, 2022

Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting

Read More

May 04, 2022

Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022

Read More